Assessing the Economic Value of Cancer Prevention

  • Benjamin M. CraigEmail author


It is critically important to discuss and quantify the economic value of cancer prevention, so that resources can be properly allocated toward its activities. In cancer prevention, there ain’t such thing as a free lunch. Building from four fundamental questions, this chapter provides an overview of how its value can be defined and assessed. Common concepts, such as benefit-risk, cost-effectiveness, budget-impact, and QALY, are explained with examples from the literature.


Neoplasms Economics Cost and cost analysis Patient preference Decision-making 


  1. Aaron AS, John M (1998) Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Mak 18(2_suppl):S68–S80CrossRefGoogle Scholar
  2. Alberini A, Scasny M (2018) The benefits of avoiding cancer (or dying from cancer): evidence from a four- country study. J Health Econ 57:249–262CrossRefGoogle Scholar
  3. Brand DA, Kliger AS (1999) Planning for a kidney transplant: is my doctor listening? JAMA 282(7):691–694CrossRefGoogle Scholar
  4. Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21(2):271–292CrossRefGoogle Scholar
  5. Brown AD, Garber AM (1999) Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA 281(4):347–353CrossRefGoogle Scholar
  6. Brown ML, Lipscomb J, Snyder C (2001) The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health 22:91–113CrossRefGoogle Scholar
  7. Bruner DW, Movsas B, Konski A, Roach M, Bondy M, Scarintino C, Scott C, Curran W (2004) Outcomes research in cancer clinical trial cooperative groups: the RTOG model. Qual Life Res 13(6):1025–1041CrossRefGoogle Scholar
  8. Dobler CC, Midthun DE, Montori VM (2017) Quality of shared decision making in lung cancer screening: the right process, with the right partners, at the right time and place. Mayo Clin Proc 92(11):1612–1616CrossRefGoogle Scholar
  9. Eddy DM (1990) Screening for cervical cancer. Ann Intern Med 113(3):214–226CrossRefGoogle Scholar
  10. Elbasha EH, Dasbach EJ, Insinga RP (2007) Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13(1):28–41CrossRefGoogle Scholar
  11. Esser M, Brunner H (2003) Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia. PharmacoEconomics 21(18):1295–1313CrossRefGoogle Scholar
  12. Ferrans CE (2004) Definitions and conceptual models of quality of life. In: Gotay CC, Snyder C, Lipscomb J (eds) Outcomes assessment in cancer: measures, methods and applications. Cambridge University Press, Cambridge, pp 14–30CrossRefGoogle Scholar
  13. Fryback DG, Craig BM (2004) Measuring economic outcomes of cancer. J Natl Cancer Inst Monogr (33):134–141CrossRefGoogle Scholar
  14. Gold MR, Stevenson D, Fryback DG (2002) HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population health. Annu Rev Public Health 23:115–134CrossRefGoogle Scholar
  15. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E (2004) Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96(8):604–615CrossRefGoogle Scholar
  16. Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA (1999) The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 130(2):97–107CrossRefGoogle Scholar
  17. Grant M, Ferrell B, Dean G, Uman G, Chu D, Krouse R (2004) Revision and psychometric testing of the City of Hope Quality of Life-Ostomy Questionnaire. Qual Life Res 13(8):1445–1457CrossRefGoogle Scholar
  18. Houts PS, Lipton A, Harvey HA, Martin B, Simmonds MA, Dixon RH, Longo S, Andrews T, Gordon RA, Meloy J et al (1984) Nonmedical costs to patients and their families associated with outpatient chemotherapy. Cancer 53(11):2388–2392CrossRefGoogle Scholar
  19. Hunter S, Love-Jackson K, Abdulla R, Zhu W, Lee JH, Wells KJ, Roetzheim R (2010) Sun protection at elementary schools: a cluster randomized trial. J Natl Cancer Inst 102(7):484–492CrossRefGoogle Scholar
  20. Johnson E, Dominici F, Griswold M, Zeger SL (2003) Disease cases and their medical costs attributable to smoking: an analysis of the national medical expenditure survey. J Econ 112(1):135–151CrossRefGoogle Scholar
  21. Kim B, Lairson DR, Chung TH, Kim J, Shokar NK (2017) Budget impact analysis of against colorectal cancer in our neighborhoods (ACCION): a successful community-based colorectal cancer screening program for a medically underserved minority population. Value Health 20(6):809–818CrossRefGoogle Scholar
  22. Kozma CM, Reeder CE, Schulz RM (1993) Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther 15(6):1121–1132. discussion 1120Google Scholar
  23. Kulasingam SL, Myers ER (2003) Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290(6):781–789CrossRefGoogle Scholar
  24. Laverty AA, Watt HC, Arnott D, Hopkinson NS (2014) Standardised packaging and tobacco-industry-funded research. Lancet 383(9926):1384CrossRefGoogle Scholar
  25. Lee G, Lee Y, Lee H, Hong J, Yang J (2015) Value of a statistical life estimation of carcinogenic chemicals for socioeconomic analysis in Korea. Environ Health Toxicol 30 Suppl:s2015005CrossRefGoogle Scholar
  26. Levine MN, Ganz PA, Haller DG (2007) Economic evaluation in the journal of clinical oncology: past, present, and future. J Clin Oncol 25(6):614–616CrossRefGoogle Scholar
  27. Lipscomb J, Donaldson MS, Hiatt RA (2004) Cancer outcomes research and the arenas of application. J Natl Cancer Inst Monogr (33):1–7CrossRefGoogle Scholar
  28. Lipscomb J, Snyder CF (2002) The Outcomes of Cancer Outcomes Research: focusing on the National Cancer Institute’s quality-of-care initiative. Med Care 40(6 Suppl):Iii3–Ii10PubMedGoogle Scholar
  29. Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JD (2000) Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 92(7):557–563CrossRefGoogle Scholar
  30. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K (2002) Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287(18):2372–2381CrossRefGoogle Scholar
  31. Marshall DA, Johnson FR, Kulin NA, Ozdemir S, Walsh JM, Marshall JK, Van Bebber S, Phillips KA (2009) How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ 18(12):1420–1439CrossRefGoogle Scholar
  32. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P (2007) Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices—budget impact analysis. Value Health 10(5):336–347CrossRefGoogle Scholar
  33. O’Brien BJ, Rusthoven J, Rocchi A, Latreille J, Fine S, Vandenberg T, Laberge F (1993) Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CMAJ 149(3):296–302PubMedPubMedCentralGoogle Scholar
  34. Pope TM, Lessler D (2017) Revolutionizing informed consent: empowering patients with certified decision aids. Patient 10(5):537–539CrossRefGoogle Scholar
  35. Ramsey SD, Mandelson MT, Berry K, Etzioni R, Harrison R (2003) Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer. Gastroenterology 125(6):1645–1650CrossRefGoogle Scholar
  36. Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, Rothman M (2000) Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 9(8):887–900CrossRefGoogle Scholar
  37. Sculpher M, Palmer MK, Heyes A (2000) Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. PharmacoEconomics 17(4):361–370CrossRefGoogle Scholar
  38. Sferra S, Erkmen C, Ma G, Cheng J, Kaiser L, DiSesa V (2017) Online decision AID vs option grid in shared decision making prior to lung cancer screening. Chest 152(4, Supplement):A1122CrossRefGoogle Scholar
  39. Sirgy MJ, Michalos AC, Ferriss AL, Easterlin RA, Patrick D, Pavot W (2006) The quality-of-life (QOL) research movement: past, present, and future. Soc Indic Res 76(3):343–466CrossRefGoogle Scholar
  40. Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Thomson R, Trevena L (2017) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (4):Cd001431Google Scholar
  41. Staquet M, Aaronson NK (1992) Health-related quality of life research. Qual Life Res 1(1):3CrossRefGoogle Scholar
  42. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, Nefcy P (1995) Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 87(6):417–426CrossRefGoogle Scholar
  43. Tengs TO, Wallace A (2000) One thousand health-related quality-of-life estimates. Med Care 38(6):583–637CrossRefGoogle Scholar
  44. Tosteson AN, Stout NK, Fryback DG, Acharyya S, Herman BA, Hannah LG, Pisano ED (2008) Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med 148(1):1–10CrossRefGoogle Scholar
  45. Tsao H, Rogers GS, Sober AJ (1998) An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol 38(5 Pt 1):669–680CrossRefGoogle Scholar
  46. Viscusi WK, Huber J, Bell J (2014) Assessing whether there is a cancer premium for the value of a statistical life. Health Econ 23(4):384–396CrossRefGoogle Scholar
  47. Wagner JL (1997) Cost-effectiveness of screening for common cancers. Cancer Metastasis Rev 16(3–4):281–294CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of EconomicsUniversity of South FloridaTampaUSA

Personalised recommendations